95-7634. Taleigh Corporation, et al.; Proposed Consent Agreement With Analysis to Aid Public Comment  

  • [Federal Register Volume 60, Number 60 (Wednesday, March 29, 1995)]
    [Notices]
    [Pages 16148-16154]
    From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
    [FR Doc No: 95-7634]
    
    
    
    -----------------------------------------------------------------------
    
    FEDERAL TRADE COMMISSION
    [File No. 912 3232]
    
    
    Taleigh Corporation, et al.; Proposed Consent Agreement With 
    Analysis to Aid Public Comment
    
    AGENCY: Federal Trade Commission.
    
    ACTION: Proposed consent agreement.
    
    -----------------------------------------------------------------------
    
    SUMMARY: In settlement of alleged violations of federal law prohibiting 
    unfair acts and practices and unfair methods of competition, this 
    consent agreement, accepted subject to final Commission approval, would 
    prohibit, among other things, two marketing corporations and the owner 
    from misrepresenting that any product is new or unique, the existence 
    or conclusions of any test or study, or that an endorsement for any 
    product represents the typical experience of people who use it. The 
    consent agreement would require the respondents to possess scientific 
    evidence to substantiate any representation regarding the performance, 
    benefits, efficacy or safety of any weight-loss or stop-smoking 
    product, or of any food, dietary supplement, drug, or device. In 
    addition, the consent agreement would require the owner to post a 
    $300,000 performance bond, or to establish an escrow account in the 
    amount of $300,000, as a condition of advertising, promoting, selling 
    or distributing any weight-loss or smoking deterrent or cessation 
    product.
    
    DATES: Comments must be received on or before May 30, 1995.
    
    ADDRESSES: Comments should be directed to: FTC/Office of the Secretary, 
    Room 159, 6th St. and Pa. Ave., N.W., Washington, D.C. 20580.
    
    FOR FURTHER INFORMATION CONTACT:
    Joel Winston or Richard Cleland, FTC/S-4002, Washington, D.C. 20580. 
    (202) 326-3153 or 326-3088.
    
    SUPPLEMENTARY INFORMATION: Pursuant to Section 6(f) of the Federal 
    Trade Commission Act, 38 Stat. 721, 15 U.S.C. 46 and Section 2.34 of 
    the Commission's Rules of Practice (16 CFR 2.34), notice is hereby 
    given that the following consent agreement containing a consent order 
    to cease and desist, having been filed with and accepted, subject to 
    final [[Page 16149]] approval, by the Commission, has been placed on 
    the public record for a period of sixty (60) days. Public comment is 
    invited. Such comments or views will be considered by the Commission 
    and will be available for inspection and copying at its principal 
    office in accordance with Section 4.9(b)(6)(ii) of the Commission's 
    Rules of Practice (16 CFR 4.9(b)(6)(ii)).
    
        In the Matter of: Raleigh Corporation, and Choice Diet Products, 
    Inc., corporations; and William J. Santamaria, individually and as 
    an officer and director of said corporations.
    
    Agreement Containing Consent Order To Cease and Desist
    
        The Federal Trade Commission having initiated an investigation of 
    Taleigh Corporation, a Florida corporation, Choice Diet Products, Inc., 
    a New York corporation, and William J. Santamaria, individually and as 
    an officer of said corporations (``proposed respondents''), and it now 
    appearing that proposed respondents are willing to enter into an 
    agreement containing an order to cease and desist from the use of the 
    acts and practices being investigated,
        It is hereby agreed by and between Taleigh Corporation, a Florida 
    corporation, by its duly authorized officer, Choice Diet Products, 
    Inc., a New York corporation, by its duly authorized officer, and 
    William J. Santamaria, individually and as an officer of said 
    corporation, and their attorney, and counsel for the Federal Trade 
    Commission that:
        1. Proposed respondent Taleigh Corporation, formerly known as 
    Taleigh, Inc., a Florida corporation, is organized, exists and does 
    business under and by virtue of the laws of the State of Florida. At 
    times relevant hereto, its office and principal place of business was 
    located at 4800 N.W. Boca Raton Boulevard, Boca Raton, FL 33431.
        Proposed respondent Choice Diet Products, Inc., a New York 
    corporation, is organized, exists and does business under and by virtue 
    of the laws of the State of New York. At times relevant hereto, its 
    office and principal place of business was located at 4800 N.W. Boca 
    Raton Boulevard, Boca Raton, FL 33431.
        Proposed respondent William J. Santamaria is an officer of said 
    corporations. He formulates, directs and controls the policies, acts 
    and practices of said corporation and his address is 20640 Baybrooke 
    Court, Boca Raton, FL 33498.
        2. Proposed respondents admit all the jurisdictional facts set 
    forth in the draft of complaint.
        3. Proposed respondents waive:
        (a) Any further procedural steps;
        (b) The requirement that the Commission's decision contain a 
    statement of findings of fact and conclusions of law; and
        (c) All rights to seek judicial review or otherwise to challenge or 
    contest the validity of the Order entered pursuant to this agreement.
        4. This agreement shall not become part of the public record of the 
    proceeding unless and until it is accepted by the Commission. If this 
    agreement is accepted by the Commission it, together with the draft of 
    complaint contemplated thereby, will be placed on the public record for 
    a period of sixty (60) days and information in respect thereto publicly 
    released. The Commission thereafter may either withdraw its acceptance 
    of this agreement and so notify the proposed respondents, in which 
    event it will take such action as it may consider appropriate, or issue 
    and serve its complaint (in such form as circumstances may require) and 
    decision in disposition of this proceeding.
        5. This agreement is for settlement purposes only and does not 
    constitute an admission by proposed respondents that the law has been 
    violated as alleged in the draft of complaint or that the facts as 
    alleged in the draft of complaint, other than the jurisdictional facts, 
    are true.
        6. This agreement contemplates that, if it is accepted by the 
    Commission, and if such acceptance is subsequently withdrawn by the 
    Commission pursuant to the provision of Sec. 2.34 of the Commission's 
    Rules, the Commission may, without further notice to the proposed 
    respondents, (1) issue its complaint corresponding in form and 
    substance with the draft of complaint and its decision containing the 
    following order to cease and desist in disposition of the proceeding 
    and (2) make information public with respect thereto. When so entered, 
    the order to cease and desist shall have the same force and effect and 
    may be altered, modified or set aside in the same manner and within the 
    same time provided by statute for other orders. The order shall become 
    final upon service. Delivery by the U.S. Postal Service of the 
    complaint and decision containing the agreed-to order to proposed 
    respondent's addresses as stated in this agreement shall constitute 
    service. Proposed respondents waive any right they may have to any 
    other manner of service. The complaint may be used in construing the 
    terms of the order, and no agreement, understanding, representation, or 
    interpretation not contained in the order or in the agreement may be 
    used to vary or contradict the terms of the order.
        7. Proposed respondents have read the proposed complaint and order 
    contemplated hereby. They understand that once the order has been 
    issued, they will be required to file one or more compliance reports 
    showing that they have fully complied with the order. Proposed 
    respondents further understand that they may be liable for civil 
    penalties in the amount provided by law for each violation of the order 
    after it becomes final.
    
    Order
    
        For purposes of this Order:
        1. ``Clearly and prominently'' as used herein shall mean as 
    follows:
        (a) In a television or videotape advertisement: (1) an audio 
    disclosure shall be delivered in a volume and cadence and for a 
    duration sufficient for an ordinary consumer to hear and comprehend it; 
    and (2) a video disclosure shall be of a size and shade, and shall 
    appear on the screen for a duration, sufficient for an ordinary 
    consumer to read and comprehend it.
        (b) In a print advertisement, the disclosure shall be in close 
    proximity to the representation that triggers the disclosure in at 
    least twelve (12) point type.
        (c) In a radio advertisement, the disclosure shall be delivered in 
    a volume and cadence sufficient for an ordinary consumer to hear and 
    comprehend it.
        2. ``Competent and reliable scientific evidence'' shall mean tests, 
    analyses, research, studies, or other evidence based on the expertise 
    of professionals in the relevant area that has been conducted and 
    evaluated in an objective manner by persons qualified to do so, using 
    procedures generally accepted in the profession to yield accurate and 
    reliable results.
        3. ``Purchase price'' shall mean all amounts paid to respondents in 
    cash or by check, or charged to a consumer's credit card account or 
    debited from a consumer's checking account, including, where 
    applicable, sales tax, and any charges not authorized by consumers to 
    be charged to their charge card accounts or debited from their checking 
    accounts, provided however, with regard to Part XIV, purchase price 
    shall not include shipping or handling charges if such charges are not 
    included in respondents' guarantee or refund offer.
        4. ``Weight-loss product'' shall mean any product or program 
    designed or used to prevent weight gain or to produce weight loss, 
    reduction or [[Page 16150]] elimination of fat, slimming, or caloric 
    deficit in a user of the product or program.
        5. ``Smoking deterrent or cessation product'' shall mean any 
    product or program designed to aid or assist the user to stop or reduce 
    the cigarette urge, break the cigarette habit, or stop or reduce 
    smoking.
    
    I
    
        It is ordered that respondents, Taleigh Corporation and Choice Diet 
    Products, Inc., corporations, their successors and assigns, and their 
    officers; and William J. Santamaria, individually and as an officer and 
    director of the corporate respondents; and respondents' agents, 
    representatives, and employees, directly or through any partnership, 
    corporation, subsidiary, division, or other device, in connection with 
    the manufacturing, advertising, packaging, labeling, promotion, 
    offering for sale, sale, or distribution of FormulaTrim 3000, MegaLoss 
    1000, MegaLoss 3000, MiracleTrim, or any other weight-loss product 
    containing phenylpropanolamine as the active ingredient, in or 
    affecting commerce, as ``commerce'' is defined in the Federal Trade 
    Commission Act, do forthwith cease and desist from representing, in any 
    manner, directly or by implication, that:
        A. Such product causes or assists in causing rapid weight loss;
        B. Such product causes or assists in causing substantial weight 
    loss without the need to exercise or reduce caloric intake;
        C. Such product is new or unique or contains a new or unique 
    ingredient;
        D. Such product causes the burning of more body fat than five hours 
    of aerobics, running ten miles nonstop, swimming two and a half miles, 
    exercising six hours nonstop, or any similar exercise activity; or
        E. Such product contains an active ingredient that, prior to the 
    sale of such product, was available only through doctors.
    
    II
    
        It is further ordered that respondents, Taleigh Corporation and 
    Choice Diet Products, Inc., corporations, their successors and assigns, 
    and their officers; and William J. Santamaria, individually and as an 
    officer and director of the corporate respondents; and respondents' 
    agents, representatives, and employees, directly or through any 
    partnership, corporation, subsidiary, division, or other device, in 
    connection with the manufacturing, advertising, packaging, labeling, 
    promotion, offering for sale, sale, or distribution of any weight-loss 
    product in or affecting commerce, as ``commerce'' is defined in the 
    Federal Trade Commission Act, do forthwith cease and desist from 
    representing, in any manner, directly or by implication, that such 
    weight-loss product has any effect on weight or body size, unless 
    respondents disclose, clearly and prominently, and, in a television or 
    videotape advertisement, simultaneously in both the audio and video 
    portions of the advertisement, that reducing caloric intake and/or 
    increasing exercise is required to lose weight; provided however, that 
    this disclosure shall not be required if respondents possess and rely 
    upon competent and reliable scientific evidence demonstrating that such 
    product is effective without reducing caloric intake and/or increasing 
    exercise.
    
    III
    
        It is further ordered that respondents, Taleigh Corporation and 
    Choice Diet Products, Inc., corporations, their successors and assigns, 
    and their officers; and William J. Santamaria, individually and as an 
    officer and director of the corporate respondents; and respondents' 
    agents, representatives, and employees, directly or through any 
    partnership, corporation, subsidiary, division, or other device, in 
    connection with the manufacturing, advertising, packaging, labeling, 
    promotion, offering for sale, sale, or distribution of any product or 
    program, in or affecting commerce, as ``commerce'' is defined in the 
    Federal Trade Commission Act, do forthwith cease and desist from 
    representing, in any manner, directly or by implication, that:
        A. Such product or program causes or assists in causing weight 
    loss, or assists in maintaining weight loss;
        B. Such product or program causes or assists in causing weight loss 
    without exercise or reducing caloric intake;
        C. Such product or program causes the burning of more body fat than 
    any amount of exercise activity; or
        D. Such product or program causes or assists the user to stop or 
    reduce smoking easily;
    unless such representation is true, and, at the time of making such 
    representation, respondents possess and rely upon competent and 
    reliable scientific evidence that substantiates the representation.
    
    IV
    
        It is further ordered that respondents, Taleigh Corporation and 
    Choice Diet Products, Inc., corporations, their successors and assigns, 
    and their officers; and William J. Santamaria, individually and as an 
    officer and director of the corporate respondents; and respondents' 
    agents, representatives, and employees, directly or through any 
    partnership, corporation, subsidiary, division, or other device, in 
    connection with the manufacturing, advertising, packaging, labeling, 
    promotion, offering for sale, sale, or distribution of Nicotain, or any 
    substantially similar product or program, in or affecting commerce, as 
    ``commerce'' is defined in the Federal Trade Commission Act, do 
    forthwith cease and desist from representing, in any manner, directly 
    or by implication, that:
        A. Such product or program enables users to stop smoking easily; or
        B. Such product or program works through a mechanism substantially 
    similar or equivalent to a prescription smoking deterrent patch.
    
    V
    
        It is further ordered that respondents, Taleigh Corporation and 
    Choice Diet Products, Inc., corporations, their successors and assigns, 
    and their officers; and William J. Santamaria, individually and as an 
    officer and director of the corporate respondents; and respondents' 
    agents, representatives, and employees, directly or through any 
    partnership, corporation, subsidiary, division, or other device, in 
    connection with the manufacturing, advertising, packaging, labeling, 
    promotion, offering for sale, sale, or distribution of Nicotain, or any 
    other smoking deterrent cessation product, in or affecting commerce, as 
    ``commerce'' is defined in the Federal Trade Commission Act, do 
    forthwith cease and desist from making, in any manner, directly or by 
    implication, any misrepresentation, including through the name of the 
    product, concerning the nature or mechanism of operation of such 
    product, including, but not limited to, that such product contains 
    nicotine or works through a mechanism substantially similar or 
    equivalent to a prescription smoking deterrent patch.
    
    VI
    
        It is further ordered that respondents, Taleigh Corporation and 
    Choice Diet Products, Inc., corporations, their successors and assigns, 
    and their officers; and William J. Santamaria, individually and as an 
    officer and director of the corporate respondents; and respondents' 
    agents, representatives, and employees, directly or through any 
    partnership, corporation, subsidiary, division, or other device, in 
    [[Page 16151]] connection with the manufacturing, advertising, 
    packaging, labeling, promotion, offering for sale, sale, or 
    distribution of any product or program, in or affecting commerce, as 
    ``commerce'' is defined in the Federal Trade Commission Act, do 
    forthwith cease and desist from misrepresenting, in any manner, 
    directly or by implication, that:
        A. Such product or program is new or unique or contains a new or 
    unique ingredient;
        B. Consumers who order the product or program will receive a 
    personal consultation from a physician, medical professional or weight-
    loss counselor; or
        C. Any endorsement (as ``endorsement'' is defined in 16 C.F.R. 
    Sec. 255.0(b)) of such product or program represents the typical or 
    ordinary experience of members of the public who use the product or 
    program.
    
    VII
    
        It is further ordered that respondents, Taleigh Corporation and 
    Choice Diet Products, Inc., corporations, their successors and assigns, 
    and their officers; and William J. Santamaria, individually and as an 
    officer and director of the corporate respondents; and respondents' 
    agents, representatives, and employees, directly or through any 
    partnership, corporation, subsidiary, division, or other device, in 
    connection with the manufacturing, advertising, packaging, labeling, 
    promotion, offering for sale, sale, or distribution of any product or 
    program, in or affecting commerce, as ``commerce'' is defined in the 
    Federal Trade Commission Act, do forthwith cease and desist from 
    failing to disclose, clearly and prominently, a material connection, 
    where one exists, between a person providing an endorsement of any 
    product or program, as ``endorsement'' is defined in 16 C.F.R. 
    Sec. 255.0(b), and any respondent, or any other individual or entity 
    manufacturing, labeling, advertising, promoting, offering for sale, 
    selling, or distributing such product or program. For purposes of this 
    Order, ``material connection'' shall mean any relationship that might 
    materially affect the weight or credibility of the endorsement and 
    would not reasonably be expected by consumers.
    
    VIII
    
        It is further ordered that respondents, Taleigh Corporation and 
    Choice Diet Products, Inc., corporations, their successors and assigns, 
    and their officers; and William J. Santamaria, individually and as an 
    officer and director of the corporate respondents; and respondents' 
    agents, representatives, and employees, directly or through any 
    partnership, corporation, subsidiary, division, or other device, in 
    connection with the manufacturing, advertising, packaging, labeling, 
    promotion, offering for sale, sale, or distribution of any product or 
    program, in or affecting commerce, as ``commerce'' is defined in the 
    Federal Trade Commission Act, do forthwith cease and desist from 
    misrepresenting, in any manner, directly or by implication, the 
    contents, validity, results, conclusions, or interpretations of any 
    test or study.
    
    IX
    
        It is further ordered that respondents, Taleigh Corporation and 
    Choice Diet Products, Inc., corporations, their successors and assigns, 
    and their officers; and William J. Santamaria, individually and as an 
    officer and director of the corporate respondents; and respondents' 
    agents, representatives, and employees, directly or through any 
    partnership, corporation, subsidiary, division, or other device, in 
    connection with the manufacturing, advertising, packaging, labeling, 
    promotion, offering for sale, sale, or distribution of any product or 
    program, in or affecting commerce, as ``commerce'' is defined in the 
    Federal Trade Commission Act, do forthwith cease and desist from 
    representing, in any manner, directly or by implication, that:
        A. Such product or program does not cause any dangerous side 
    effects, nervous jitters, or insomnia;
        B. Such product or program burns, reduces, or diminishes body fat; 
    or
        C. Such product or program significantly shrinks fat cells;
    
    unless, at the time of making such representation, respondents possess 
    and rely upon competent and reliable scientific evidence that 
    substantiates the representation.
    
    X
    
        It is further ordered that respondents, Taleigh Corporation and 
    Choice Diet Products, Inc., corporations, their successors and assigns, 
    and their officers; and William J. Santamaria, individually and as an 
    officer and director of the corporate respondents; and respondents' 
    agents, representatives, and employees, directly or through any 
    partnership, corporation, subsidiary, division, or other device, in 
    connection with the manufacturing, advertising, packaging, labeling, 
    promotion, offering for sale, sale, or distribution of any weight-loss 
    product, smoking deterrent or cessation product, food, food or dietary 
    supplement, drug, or device, as ``food,'' ``drug,'' and ``device'' are 
    defined in Section 15 of the Federal Trade Commission Act, in or 
    affecting commerce, as ``commerce'' is defined in the Federal Trade 
    Commission Act, do forthwith cease and desist from making, in any 
    manner, directly or by implication, any representation regarding the 
    performance, benefits, efficacy, or safety of any such product, unless, 
    at the time of making such representation, respondents possess and rely 
    upon competent and reliable scientific evidence that substantiates the 
    representation.
    
    XI
    
        Nothing in this Order shall prohibit respondents from making any 
    representation that is specifically permitted in labeling for any 
    product by regulations promulgated by the Food and Drug Administration 
    pursuant to the Nutrition Labeling and Education Act of 1990.
    
    XII
    
        Nothing in this Order shall prohibit respondents from making any 
    representation for any drug that is permitted in labeling for any such 
    drug under any tentative final or final standard promulgated by the 
    Food and Drug Administration, or under any new drug application 
    approved by the Food and Drug Administration.
    
    XIII
    
        It is further ordered that respondents, Taleigh Corporation and 
    Choice Diet Products, Inc., corporations, their successors and assigns, 
    and their officers; and William J. Santamaria, individually and as an 
    officer and director of the corporate respondents; and respondents' 
    agents, representatives, and employees, directly or through any 
    partnership, corporation, subsidiary, division, or other device, in 
    connection with the manufacturing, advertising, packaging, labeling, 
    promotion, offering for sale, sale, or distribution of any product or 
    program, in or affecting commerce, as ``commerce'' is defined in the 
    Federal Trade Commission Act, do forthwith cease and desist from 
    charging a consumer's credit card account or debiting a consumer's 
    checking account in an amount in excess of the amount affirmatively 
    authorized by the consumer.
    
    XIV
    
        It is further ordered that respondents, Taleigh Corporation and 
    Choice Diet Products, Inc., corporations, their successors and assigns, 
    and their [[Page 16152]] officers; and William J. Santamaria, 
    individually and as an officer and director of the corporate 
    respondents; and respondents' agents, representatives, and employees, 
    directly or through any partnership, corporation, subsidiary, division, 
    or other device, in connection with the manufacturing, advertising, 
    packaging, labeling, promotion, offering for sale, sale, or 
    distribution of any product or program, in or affecting commerce, as 
    ``commerce'' is defined in the Federal Trade Commission Act, do 
    forthwith cease and desist from:
        A. Representing, directly or by implication, that consumers can 
    receive a refund, through such terms as ``money back guarantee'' or 
    similar terms, unless respondents refund the full purchase price at the 
    consumer's request in accordance with the provisions of this Part;
        B. Failing to disclose, clearly and prominently, any material 
    limitations or conditions that apply to a guarantee, warranty or refund 
    policy;
        C. Failing to comply, where applicable, with the requirements of 
    Section 166 of the Truth in Lending Act, 15 U.S.C. Sec. 1666e and 12 
    CFR 226.12(e)(1); and
        D. Failing to refund the full purchase price in accordance with the 
    terms of a guarantee, warranty or refund policy within a reasonable 
    period of time after a consumer complies with the conditions for 
    receiving a refund. For purposes of this Part, ``a reasonable period of 
    time'' shall be:
        (1) That period of time specified in respondents' solicitation if 
    such period is clearly and prominently disclosed to the consumer in the 
    solicitation; or
        (2) If no period of time is clearly and prominently disclosed, a 
    period of thirty (30) days following the date that the consumer 
    complies with the conditions for receiving a refund.
    
    For purposes of determining whether a consumer has complied with the 
    conditions for receiving a refund, the date for determining whether the 
    consumer has returned the product or program within the specified time 
    shall be the date the consumer mails or causes the product or program 
    to be shipped to the respondents or respondents' designated agents.
    
    XV
    
        It is further ordered that respondents, Taleigh Corporation and 
    Choice Diet Products, Inc., corporations, their successors and assigns, 
    and their officers; and William J. Santamaria, individually and as an 
    officer and director of the corporate respondents; and respondents' 
    agents, representatives, and employees, directly or through any 
    partnership, corporation, subsidiary, division, or other device, in 
    connection with the manufacturing, advertising, packaging, labeling, 
    promotion, offering for sale, sale, or distribution of any product or 
    program, in or affecting commerce, as ``commerce'' is defined in the 
    Federal Trade Commission Act, do forthwith cease and desist from 
    violating any provision of The Mail or Telephone Order Merchandise 
    Rule, 16 CFR Part 435, as amended, effective March 1, 1994, 58 F.R. 
    49095.
    
    XVI
    
        It is further ordered that respondent William J. Santamaria, and 
    respondent Santamaria's agents, representatives, and employees, 
    directly or through any partnership, corporation, subsidiary, division, 
    joint venture or other device, do forthwith cease and desist from 
    advertising, promoting, offering for sale, selling, or distributing any 
    weight-loss product or smoking deterrent or cessation product to the 
    general public, unless, prior to advertising, promoting, offering for 
    sale, selling, or distributing to the general public any such product, 
    respondent Santamaria first obtains a performance bond in the principal 
    sum of three hundred thousand dollars ($300,000). Said bond shall be 
    conditioned upon compliance by respondent Santamaria with the 
    provisions of the Federal Trade Commission Act, and with the provisions 
    of this Order. The bond shall be deemed continuous and remain in full 
    force and effect as long as respondent Santamaria continues to 
    advertise, promote, offer for sale, sell, or distribute any weight-loss 
    product or smoking deterrent or cessation product, directly or 
    indirectly, to the general public, and for at least five (5) years 
    after he has ceased any such activity. The bond shall cite this Order 
    as the subject matter of the bond and provide surety against respondent 
    Santamaria's failure to pay consumer redress or disgorgement as set 
    forth herein. Such performance bond shall be an insurance agreement 
    providing surety issued by a surety company that is admitted to do 
    business in a state in which respondent Santamaria is doing business 
    and that holds a Federal Certificate of Authority as Acceptable Surety 
    on Federal Bond and Reinsuring.
        Respondent Santamaria shall provide a copy of such performance bond 
    to the associate director of the Federal Trade Commission's Division of 
    Enforcement, 6th Street & Pennsylvania Avenue, N.W., Washington, D.C. 
    20580, prior to the commencement of any business for which such bond is 
    required.
        Provided, however, in lieu of a performance bond, respondent 
    Santamaria may establish and fund, pursuant to the terms set forth 
    herein, an escrow account in the principal sum of three hundred 
    thousand dollars ($300,000) in cash, or such other assets of equivalent 
    value, which the Commission, or its representative, in its sole 
    discretion may approve. Respondent Santamaria shall maintain such 
    amount in that account for so long as he continues to advertise, 
    promote, offer for sale, sell, or distribute any weight-loss product or 
    smoking deterrent or cessation product, directly or indirectly, to the 
    general public, and for at least five (5) years after he has ceased any 
    such activity. Respondent Santamaria shall pay all costs associated 
    with the creation, funding, operation, and administration of the escrow 
    account. The Commission, or its representative, shall, in its sole 
    discretion, select the escrow agent. The escrow agreement shall be in 
    substantially the form attached to this Order as Exhibit A.
        The performance bond or escrow agreement shall provide that the 
    surety company or escrow agent, within thirty days following receipt of 
    notice that a final judgment or an order of the Commission against 
    respondent Santamaria for consumer redress or disgorgement in an action 
    brought under the provisions of the Federal Trade Commission Act has 
    been entered, or, in the case of an order of the Commission, has become 
    final, finding that he has violated the terms of this Order or the 
    Federal Trade Commission Act, and determining the amount of consumer 
    redress or disgorgement to be paid, shall pay to the Commission so much 
    of the performance bond or funds of the escrow account as does not 
    exceed the amount of consumer redress or disgorgement ordered, and 
    which remains unsatisfied at the time notice is provided to the surety 
    company or escrow agent, provided that, if respondent Santamaria has 
    agreed to the entry of a court order or an order of the Commission, a 
    specific finding that Santamaria violated the terms of this Order or 
    the provisions of the Federal Trade Commission Act shall not be 
    necessary. A copy of the notice provided for herein shall be mailed to 
    respondent Santamaria at his last known address.
        Respondent Santamaria may not disclose the existence of the 
    performance bond or escrow account to any consumer, or other purchaser 
    or prospective purchaser, to whom a [[Page 16153]] covered product is 
    advertised, promoted, offered for sale, sold, or distributed, without 
    also disclosing at the same time and in a like manner that the 
    performance bond or escrow account is required by order of the Federal 
    Trade Commission in settlement of charges that respondent Santamaria 
    engaged in false and misleading representations.
    
    XVII
    
        It is further ordered that respondents, Taleigh Corporation and 
    Choice Diet Products, Inc., shall:
        A. Within thirty (30) days after service of this Order, provide a 
    copy of this Order to each of respondents' current principals, 
    officers, directors, and managers, and to all personnel, agents, and 
    representatives having sales, advertising, or policy responsibility 
    with respect to the subject matter of this Order; and
        B. For a period of five (5) years from the date of issuance of this 
    Order, provide a copy of this Order to each respondents' future 
    principals, officers, directors, and managers, and to all personnel, 
    agents, and representatives having sales, advertising, or policy 
    responsibility with respect to the subject matter of this Order who are 
    associated with respondents or any subsidiary, successor, or assign, 
    within three (3) days after the person assumes his or her 
    responsibilities.
    
    XVIII
    
        It is further ordered that for five (5) years after the last date 
    of dissemination of any representation covered by this Order, 
    respondents, or their successors and assigns, shall maintain and upon 
    request make available to the Federal Trade Commission or its staff for 
    inspection and copying:
        A. All materials that are relied upon in disseminating such 
    representation; and
        B. All tests, reports, studies, surveys, demonstrations or other 
    evidence in their possession or control that contradict, qualify, or 
    call into question such representation, or the basis relied upon for 
    such representation, including complaints from consumers.
    
    XIX
    
        It is further ordered that respondents, Taleigh Corporation and 
    Choice Diet Products, Inc., shall notify the Federal Trade Commission 
    at least thirty (30) days prior to any proposed change in their 
    corporate structures, including but not limited to dissolution, 
    assignment, or sale resulting in the emergence of a successor 
    corporation, the creation or dissolution of subsidiaries or affiliates, 
    the planned filing for a bankruptcy petition, or any other corporate 
    change that may affect compliance obligations arising out of this 
    Order.
    
    XX
    
        It is further ordered that respondent, William J. Santamaria, 
    shall, for a period of seven (7) years from the date of issuance of 
    this Order, notify the Commission within thirty (30) days of the 
    discontinuance of his present business or employment and of his 
    affiliation with any new business or employment. Each notice of 
    affiliation with any new business or employment shall include 
    respondent's new business address and telephone number, current home 
    address, and a statement describing the nature of the business of 
    employment and his duties and responsibilities.
    
    XXI
    
        It is further ordered that respondents, Taleigh Corporation and 
    Choice Diet Products, Inc., corporations, their successors and assigns, 
    and their officers; and William J. Santamaria, individually and as an 
    officer and director of the corporate respondents; shall, within sixty 
    (60) days after service of this Order, and at such other times as the 
    Federal Trade Commission may require, file with the Commission a 
    report, in writ ing, setting forth in detail the manner and form in 
    which they have complied with this Order.
    
    Analysis of Proposed Consent Order To Aid Public Comment
    
        The Federal Trade Commission has accepted an agreement, subject to 
    final approval, to a proposed consent order from proposed respondents 
    Taleigh Corporation, Choice Diet Products, Inc., and William J. 
    Santamaria.
        The proposed consent order has been placed on the public record for 
    sixty (60) days for reception of comments by interested persons. 
    Comments received during this period will become part of the public 
    record. After sixty (60) days, the Commission will again review the 
    agreement and the comments received and will decide whether it should 
    withdraw from the agreement and take other appropriate action or make 
    final the agreement's proposed order.
        This matter concerns advertising and trade practices related to the 
    sale of several weight-loss pills and a smoking cessation product. The 
    Commission's Complaint alleges that proposed respondents Taleigh 
    Corporation, Choice Diet Products, Inc., and William J. Santamaria made 
    a number of false claims regarding the speed and ease with which 
    consumers can burn fat and lose substantial amounts of weight with 
    proposed respondents' weight-loss pills--MegaLoss, FormulaTrim, and 
    MiracleTrim. The Complaint also alleges that proposed respondents 
    falsely promoted these products as new or unique, as causing weight 
    loss without the need for users to diet or exercise, and as providing 
    the same weight-loss benefits as exercise. With respect to MiracleTrim, 
    the Complaint also alleges that respondents falsely represented that 
    consumers who ordered MiracleTrim would receive a personal weight-loss 
    consultation from a qualified professional.
        With respect to MegaLoss, the Complaint also alleges that proposed 
    respondents represented that the product would not cause nervous 
    jitters or insomnia, or have any dangerous side effects, and that, 
    prior to the sale of MegaLoss, the active ingredient in the product was 
    not available without a prescription. The Complaint further alleges 
    that respondents represented that FormulaTrim and MegaLoss would ``burn 
    fat'' and that MegaLoss and MiracleTrim would significantly shrink 
    millions of fat cells.
        The Complaint also alleges that proposed respondents falsely and 
    misleadingly represented that they possessed and relied upon a 
    reasonable basis when they made the claims set forth above. The 
    Complaint further alleges that proposed respondents falsely represented 
    that the MegaLoss and FormulaTrim pills are scientifically proven to 
    cause significant weight loss. The Complaint also charges that proposed 
    respondents failed to disclose adequately that certain consumer 
    endorsers appearing in their advertising had a material connection to 
    proposed respondents, in that the consumers had been compensated or 
    offered significant compensation for their endorsement.
        The Complaint further alleges that proposed respondents have 
    engaged in several unfair and deceptive trade practices, including: (1) 
    Debiting consumers' bank accounts or billing consumers' credit card 
    accounts without their authorization; (2) offering a money-back 
    guarantee in their ads and then denying refunds or failing to make 
    timely refunds to consumers who have returned the product within the 
    required time period; (3) failing to deliver products at all or failing 
    to deliver products within a reasonable period of time; and (4) 
    violating the Truth in Lending Act by not processing credit charges in 
    a timely fashion.
        Regarding Nicotain, a purported smoking cessation product, the 
    Complaint charges proposed respondents with representing falsely 
    [[Page 16154]] and without a reasonable basis that Nicotain enables 
    smokers to stop smoking quickly and easily, and that it works through 
    the same mechanism as a prescription smoking deterrent patch.
        With respect to the advertising for both the weight loss pills and 
    Nicotain, the Complaint alleges that proposed respondents falsely 
    represented that consumer testimonials appearing in the ads reflect the 
    typical or ordinary experience of members of the public who have used 
    the products.
        The proposed consent order ontains provisions designed to remedy 
    the violations charged and to prevent the proposed respondent from 
    engaging in similar acts in the future.
        Part I of the proposed order prohibits proposed respondents from 
    representing that MegaLoss, FormulaTrim, and MiracleTrim, or any other 
    weight-loss product containing phenylpropanolamine as the active 
    ingredient: (1) Causes or assists in causing rapid weight loss; (2) 
    causes or assists in causing substantial weight loss without the need 
    to exercise or reduce caloric intake; (3) is new or unique or contains 
    a new or unique ingredient; (4) causes the burning of more body fat 
    than certain strenuous exercise; or (5) contains an active ingredient 
    that, prior to the sale of such product, was available only through 
    doctors.
        Part II requires the proposed respondents to disclose that diet or 
    exercise are required to lose weight in connection with any 
    representation about the effect of a weight-loss product on weight or 
    body size, unless they have competent and reliable scientific evidence 
    to the contrary. Part III prohibits proposed respondents from making 
    the types of weight-loss, fat burning and smoking cessation claims 
    alleged in the complaint to be false and unsubstantiated, unless the 
    claims are true and substantiated by competent and reliable scientific 
    evidence. Part IV prohibits proposed respondents from representing that 
    Nicotain or any substantially similar product (a) will enable smokers 
    to stop smoking easily, or (b) works through a mechanism substantially 
    similar to a prescription smoking deterrent patch. Part V prohibits any 
    misrepresentation concerning the nature or mechanism of operation of 
    any smoking cessation product.
        Part VI prohibits proposed respondents from misrepresenting that: 
    (1) Any product or program is new or unique, or contains a new or 
    unique ingredient; (2) consumers who order any product or program will 
    receive a personal consultation from a physician or medically trained 
    weight-loss counselor; or (3) the results claimed in consumer 
    testimonials constitute the typical or ordinary experience of members 
    of the public who use the advertised product or program.
        Part VII of the proposed order requires proposed respondents to 
    disclose, clearly and prominently, a material connection, where one 
    exists, between any endorser and the proposed respondents.
        Part VIII prohibits proposed respondents from misrepresenting the 
    contents, validity, results, conclusions, or interpretations of any 
    test or study. Part IX requires that proposed respondents have 
    competent and reliable scientific evidence to substantiate the 
    following categories of claims for any product or program: (1) Any 
    representations regarding dangerous side effects, nervous jitters, 
    insomnia, or any other adverse health effects; (2) any representations 
    that the product or program burns, reduces, or diminishes body fat; and 
    (3) any representations that the product or program will significantly 
    shrink fat cells. Part X requires proposed respondents to possess 
    scientific substantiation before making representations regarding the 
    performance, benefits, efficacy, or safety of any weight-loss product, 
    smoking deterrent or cessation product, food, food or dietary 
    supplement, drug, or device.
        Parts XI and XII contain safe harbors for claims that are permitted 
    on the labeling of foods and drugs under the applicable FDA 
    regulations.
        Part XIII bans proposed respondents' practice of charging a 
    consumer's credit card account of debiting a consumer's checking 
    account in excess of the amount affirmatively authorized by the 
    consumer. Under Part XIV, proposed respondents are prohibited from 
    misrepresenting the terms of a money-back guarantee and from failing to 
    provide a refund when a consumer has complied with the conditions 
    stated in the advertisement for obtaining a refund. Part XV prohibits 
    proposed respondents from failing to comply with the requirements of 
    the Commission's Mail or Telephone Order Merchandise Rule, as amended, 
    effective March 1, 1994.
        Part XVI requires that as a condition of advertising, promoting, 
    offering for sale, selling, or distributing any weight-loss product or 
    smoking deterrent or cessation product, proposed respondent Santamaria 
    either obtain a performance bond or establish an escrow account in the 
    amount of $300,000.
        Part XVII requires proposed respondents to maintain, for five (5) 
    years, all materials that support, contradict, qualify, or call into 
    question any representations they make which are covered by the 
    proposed order. Part XVIII requires the proposed corporate respondents 
    to distribute a copy of the order to current and future principals, 
    officers, directors, and managers, as well as to any employees having 
    sales, advertising, or policy responsibility with respect to the 
    subject matter of the order. Under Part XIX of the proposed order, the 
    proposed corporate respondents must notify the Federal Trade Commission 
    at least thirty (30) days prior to certain proposed changes in their 
    structures. Part XX requires that proposed respondent Santamaria, for a 
    period of seven (7) years, notify the Commission of any change in his 
    business or employment. Part XXI obliges proposed respondents to file 
    compliance reports with the Commission.
        The purpose of this analysis is to facilitate public comment on the 
    proposed order, and it is not to constitute an official interpretation 
    of the agreement and proposed order or to modify in any way their 
    terms.
    Donald S. Clark,
    Secretary.
    [FR Doc. 95-7634 Filed 3-28-95; 8:45 am]
    BILLING CODE 6750-01-M
    
    

Document Information

Published:
03/29/1995
Department:
Federal Trade Commission
Entry Type:
Notice
Action:
Proposed consent agreement.
Document Number:
95-7634
Dates:
Comments must be received on or before May 30, 1995.
Pages:
16148-16154 (7 pages)
Docket Numbers:
File No. 912 3232
PDF File:
95-7634.pdf